Suchergebnisse - "JAK inhibitor"

PubPharm (25)

1

Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort

enthalten in: Arthritis Research & Therapy | 2024

von Fujii, T. | Murata, K. | Onizawa, H. | +12

2

Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort

in: Arthritis Research & Therapy | 2024

von Takayuki Fujii | Koichi Murata | Hideo Onizawa | +12

3

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies

enthalten in: Arthritis Research & Therapy | 2023

von Baraliakos, X. | Ranza, R. | Östör, A. | +10

4

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies

enthalten in: Arthritis Research & Therapy | 2023

von Baraliakos, X. | Ranza, R. | Östör, A. | +10

5

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

enthalten in: Arthritis Research & Therapy | 2022

von Bergman, M. | Tundia, N. | Martin, N. | +5

6

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

enthalten in: Arthritis Research & Therapy | 2022

von Bergman, M. | Tundia, N. | Martin, N. | +5

7

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

enthalten in: Arthritis Research & Therapy | 2022

von Dörner, T. | van Vollenhoven, R. | Doria, A. | +6

8

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

enthalten in: Arthritis Research & Therapy | 2022

von Dörner, T. | van Vollenhoven, R. | Doria, A. | +6

9

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

in: Arthritis Research & Therapy | 2022

von Martin Bergman | Namita Tundia | Naomi Martin | +5

10

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

in: Arthritis Research & Therapy | 2022

von Thomas Dörner | Ronald F. van Vollenhoven | Andrea Doria | +6